Eli Lilly is intervening in a lawsuit filed by a trade group representing compounding pharmacies, aiming to block the FDA’s determination that the shortage of its GLP-1 medications, Mounjaro and Zepbound, has ended.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
